Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • Use of SGLT2...

Use of SGLT2 inhibitors reduces risk of dry eye disease: JAMA

Written By : Dr. Kamal Kant Kohli Published On 2022-09-27T19:30:30+05:30  |  Updated On 27 Sept 2022 7:30 PM IST
Use of SGLT2 inhibitors reduces risk of dry eye disease: JAMA
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

TAIWAN: According to the researchers of a large retrospective study reported in JAMA Network Open, one advantage of SGLT2 inhibitors in people with type 2 diabetes (T2D) may be a decreased risk of dry eye illness compared to recipients of GLP-1 RAs.

According to the International Diabetes Federation, there were 463 million people with diabetes worldwide in 2019, and an estimated of 700 million by 2045. Dry eye disease (DED) is one of the most often observed symptoms associated with type 2 diabetes, despite the fact that diabetic retinopathy is a well-known ocular consequence brought on by persistent hyperglycemia (T2D). The majority of current clinical trials and observational studies concentrate on the relationship between the use of SGLT2 inhibitors and mortality and macrovascular and microvascular problems in T2D patients. There isn't enough proof in the literature to support the claim that SGLT2 inhibitors affect DED.

"The selection of SGLT2 inhibitors for women with T2D or individuals with worse renal function should be dependent on other therapeutic considerations as there were no discernible changes in DED risks between SGLT2 inhibitor and GLP-1 receptor agonist use in these populations at high risk of DED," the authors said.

Therefore, the objective of the current study was to assess the risk of DED following the administration of SGLT2 inhibitors to T2D patients.

For this purpose, retrospective data analysis was done on 10,038 T2D patients who got SGLT2 inhibitors and 5,608 who received GLP-1 receptor agonists from Taiwan's biggest multi-institutional database. The mean age was about 59 and about half of the population was female. Clinical traits like renal function and glucose regulation were comparable between the two groups. According to the International Classification of Diseases classifications and prescriptions for drugs used to treat the condition, the main outcome was the incidence of dry eye disease. The primary result was examined in relation to the kind of diabetic medication, numerous clinical variables, and Cox proportional hazards regression models.

Conclusive points:

  • As compared to those using GLP-1 RAs (11.5 occurrences per 1000 person-years), patients newly taking SGLT2 inhibitors had a decreased incidence of DED, which resulted in a hazard ratio of 0.78 (95% CI, 0.68-0.89).
  • According to subgroup analyses, patients with T2D who used SGLT2 inhibitors had lower DED chances than those who did not, regardless of their age, sex, blood sugar level, or kidney function.
  • Results from the sensitivity analysis, which used propensity score matching, on-treatment analyses, and various follow-up intervals of 1, 2, and 3 years, were consistent with those from the primary analyses.
  • Due to systemic factors like lower testosterone levels and a higher prevalence of autoimmune illnesses, women may be more susceptible than men to develop dry eye disease.
  • As a result of tear hyperosmolarity and increased ocular surface inflammation, individuals with renal impairment or proteinuria may be more susceptible to the syndrome.

"Our results with the small absolute risk difference between SGLT2 inhibitors and GLP-1 RAs [receptor agonists] (2.5 per 1,000 person-years) could serve as an important reference for clinical decisions about prescribing various anti-diabetic drugs to delay or prevent DED in individuals with T2D," the authors wrote.

The researchers came to the conclusion that DED risk may be lower in newly prescribed SGLT2 inhibitors for T2D patients than in newly prescribed GLP-1 RAs. To examine these results, prospective studies are required, they added.

REFERENCE

Su Y, Hung J, Chang K, et al. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan. JAMA Netw Open. 2022;5(9):e2232584. doi:10.1001/jamanetworkopen.2022.32584

SGLT2 InhibitorsDry Eye DiseaseJAMA Networktype 2 diabetesHyperglycemiaGLP-1 receptor agonist
Source : JAMA Network Open
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

Relevance of Pioglitazone in Indian T2DM Care Continuum

Relevance of Pioglitazone in Indian T2DM Care Continuum

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

View All

Journal Club Today

Study Shows Combination Therapy May Improve Survival in Severe Heart Disease

Study Shows Combination Therapy May Improve Survival in Severe Heart Disease

View All

Health News Today

Health Bulletin 04/June/2025

Health Bulletin 04/June/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok